# OnCo record paper-patil-low-dose-nivolumab-jco-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-patil-low-dose-nivolumab-jco-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-patil-low-dose-nivolumab-jco-2023" ;
  schema:name "Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)"@en ;
  schema:description "Giving about one-twentieth of the standard dose of nivolumab alongside cheap oral chemotherapy nearly tripled one-year survival in advanced head and neck cancer, showing that immunotherapy can be made affordable without losing its effect."@en ;
  schema:url <https://onco.cc/key-papers/paper-patil-low-dose-nivolumab-jco-2023/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.22.01015> ;
  schema:sameAs <https://doi.org/10.1200/JCO.22.01015> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Patil VM, Noronha V, Menon N, et al." ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:institutions <https://onco.cc/institutions/tata-memorial/> ;
  onco:trials <https://onco.cc/trials/low-dose-nivolumab-tmh/> ;
  onco:people <https://onco.cc/people/patil-vijay/>, <https://onco.cc/people/prabhash-kumar/>, <https://onco.cc/people/noronha-vanita/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dose-optimisation/>, <https://onco.cc/bottlenecks/b-drug-pricing/> ;
  onco:journals <https://onco.cc/journals/jco/> .